Skip to main content

Diflucan Disease Interactions

There are 4 disease interactions with Diflucan (fluconazole).


Fluconazole (applies to Diflucan) hepatotoxicity

Major Potential Hazard, Low plausibility. Applicable conditions: Liver Disease

The use of fluconazole has been rarely associated with hepatotoxicity. Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications. Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy. Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.


  1. Franklin IM, Elias E, Hirsch C "Fluconazole-induced jaundice." Lancet 336 (1990): 565
  2. Grant SM, Clissold SP "Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses." Drugs 39 (1990): 877-916
  3. Holechek MJ "Medication review: fluconazole." ANNA J 18 (1991): 585-6
  4. Munoz P, Moreno S, Berenguer J, et al. "Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome." Arch Intern Med 151 (1991): 1020-1
  5. Wells C, Lever AM "Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge ." J Infect 24 (1992): 111-2
  6. Jacobson MA, Hanks DK, Ferrell LD "Fatal acute hepatic necrosis due to fluconazole." Am J Med 96 (1994): 188-90
  7. Gearhart MO "Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity." Ann Pharmacother 28 (1994): 1177-81
  8. "Product Information. Diflucan (fluconazole)." Roerig Division PROD (2001):
  9. Ruhnke M, Yeates RA, Pfaff G, Sarnow E, Hartmann A, Trautmann M "Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis." J Antimicrob Chemother 35 (1995): 641-7
  10. Guillaume MP, Deprez C, Cogan E "Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration." Am J Gastroenterol 91 (1996): 165-8
View all 10 references

Azole antifungals (applies to Diflucan) QT prolongation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Arrhythmias

Some azole antifungals have been associated with prolongation of the QT interval on the ECG. Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications. These drugs should be administered with caution to patients with potentially proarrhythmic conditions. Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.


  1. "Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals 1992 (2001):
  2. "Product Information. Diflucan (fluconazole)." Roerig Division PROD (2002):
  3. "Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals PROD (2002):
  4. "Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals (2022):
  5. "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals (2002):
  6. "Product Information. Noxafil (posaconazole)." Schering-Plough Corporation (2006):
  7. "Product Information. Tolsura (itraconazole)." Mayne Pharma Inc (2021):
View all 7 references

Fluconazole (applies to Diflucan) hemodialysis

Moderate Potential Hazard, High plausibility.

Fluconazole is substantially removed by hemodialysis. Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis. Fluconazole should be administered after hemodialysis.


  1. Oono S, Tabei K, Tetsuka T, Asano Y "The pharmacokinetics of fluconazole during haemodialysis in uraemic patients." Eur J Clin Pharmacol 42 (1992): 667-70
  2. Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990): 221-6
  3. "Product Information. Diflucan (fluconazole)." Roerig Division PROD (2001):

Fluconazole (applies to Diflucan) renal dysfunction

Moderate Potential Hazard, High plausibility.

Fluconazole is primarily eliminated by the kidney. Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance. Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.


  1. Toon S, Ross CE, Gokal R, Rowland M "An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole." Br J Clin Pharmacol 29 (1990): 221-6
  2. Debruyne D, Ryckelynck JP "Clinical pharmacokinetics of fluconazole." Clin Pharmacokinet 24 (1993): 10-27
  3. "Product Information. Diflucan (fluconazole)." Roerig Division PROD (2001):

Diflucan drug interactions

There are 559 drug interactions with Diflucan (fluconazole).

Report options

QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.